Related Experiment Video

Updated: Jul 7, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell

Eun-Yi Moon1, Ji-Hee Song, Kyu-Hwan Yang

  • 1Department of Bioscience and Biotechnology, Sejong University, Seoul 143-747, Korea. eunyimoon@sejong.ac.kr

Oncology Research
|March 1, 2008
PubMed

Insights

Thymosin-beta-4 (TB4) peptides increase cancer cell survival and paclitaxel resistance by inhibiting caspase-3 activity and promoting cell cycle progression. Targeting TB4 may overcome this resistance, improving chemotherapy efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Thymosin-beta-4 (TB4) is an actin-sequestering peptide found extracellularly.
  • TB4 is implicated in promoting tumor metastasis and resistance to chemotherapy, notably paclitaxel.
  • Paclitaxel resistance represents a major challenge in effective cancer treatment.

Purpose of the Study:

  • To investigate the inhibitory effect of TB4 peptides on paclitaxel-induced tumor cell death.
  • To elucidate the molecular mechanisms by which TB4 influences cancer cell survival and drug resistance.

Main Methods:

  • Assessing caspase-3 activity, G2/M cell cycle arrest, and Bcl-2 phosphorylation.
  • Utilizing TB4 peptides and small interfering RNA (siRNA) targeting TB4.
  • Employing Hela cells and gastric tumor cell lines (SNU 638, SNU 668) with varying TB4 levels.

Main Results:

  • TB4 peptide treatment increased cell survival and decreased caspase-3 activity.
  • TB4 siRNA inhibited cell viability and augmented caspase-3 activity.
  • TB4 modulated Bcl-2 phosphorylation and decreased cyclin B1 expression, impacting G2/M phase arrest.

Conclusions:

  • Soluble TB4 peptides produced by cancer cells contribute to paclitaxel resistance.
  • TB4 represents a potential therapeutic target for overcoming paclitaxel resistance in tumors.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth10:38

An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth

Published on: September 22, 2021

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...